C
Glycemic variability
8
evidence score
Also known as: glucose variability
PREVENT status
Not a PREVENT input variable.
Causal support
observational only
Score components
lit volume: 3meta-analyses: 0trials: 4.8genetic: 0MR bonus:
References (1)
0 meta-analyses / systematic reviews- Glucose Variability and Coronary Artery Disease. — Heart, lung & circulation 2018 · PMID 30527849
Clinical trials (2)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT03970044 | Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept. | COMPLETED | INTERVENTIONAL | Exenatide 2 MG, Dapagliflozin 10 MG |
| NCT02719756 | Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 | UNKNOWN | INTERVENTIONAL | Metformin, Dapagliflozin, Metformin up-titration |
Genetic associations (0)
None linked.